RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist

Area of Science:

• Pharmacology
• Neuroscience
• Medicinal Chemistry

Background:

• Selective 5-HT2B receptor antagonists are crucial for understanding normal and disease processes.
• Previous research lacked specific antagonists, hindering precise investigations into 5-HT2B receptor function.

Purpose of the Study:

• To develop novel naphthylpyrimidine-based compounds as selective 5-HT2B receptor antagonists.
• To characterize the affinity, selectivity, and functional activity of RS-127445 in vitro and in vivo.

Main Methods:

• Synthesis and screening of naphthylpyrimidine derivatives for 5-HT2B receptor antagonism.
• In vitro assays measuring receptor binding affinity, selectivity, and G-protein coupled signaling (inositol phosphates, intracellular calcium).
• In vivo studies assessing functional effects on isolated tissues (rat stomach fundus, jugular vein) and pharmacokinetic properties (bioavailability, plasma concentrations) in rats.

Main Results:

• RS-127445 demonstrated nanomolar affinity (pKi = 9.5) and high selectivity (>1000-fold) for the 5-HT2B receptor.
• Potent antagonism of 5-HT-evoked signaling and tissue responses, with no intrinsic activity observed.
• Favorable bioavailability (oral 14%, intraperitoneal 60%) and sustained receptor occupancy after intraperitoneal administration in rats.

Conclusions:

• RS-127445 is a highly selective and potent 5-HT2B receptor antagonist.
• The compound is suitable for in vivo research, offering a valuable tool for studying 5-HT2B receptor pharmacology.
• Further evaluation of RS-127445's therapeutic potential is ongoing.